|
Name |
Pyrrolo(1,2-a)pyrazine-1,4-dione, hexahydro-3-(1-methylethyl)-
|
Molecular Formula | C10H16N2O2 | |
IUPAC Name* |
3-propan-2-yl-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione
|
|
SMILES |
CC(C)C1C(=O)N2CCCC2C(=O)N1
|
|
InChI |
InChI=1S/C10H16N2O2/c1-6(2)8-10(14)12-5-3-4-7(12)9(13)11-8/h6-8H,3-5H2,1-2H3,(H,11,13)
|
|
InChIKey |
XLUAWXQORJEMBD-UHFFFAOYSA-N
|
|
Synonyms |
5654-87-5; Cyclo(Pro-Val); Pyrrolo(1,2-a)pyrazine-1,4-dione, hexahydro-3-(1-methylethyl)-; 3-propan-2-yl-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione; Cyclo(-Pro-Val); 3-Isopropylhexahydropyrrolo[1,2-a]pyrazine-1,4-dione; Cyclo-Val-Pro-diketopiperazine; Cyclo(prolylvalyl); SCHEMBL5270150; DTXSID20971985; CHEBI:181001; NSC153414; AKOS016000004; NSC 153414; NSC-153414; SB45408; NCGC00381364-02; K-73; FT-0777787; A831773; Pyrrolo[1,4-dione, hexahydro-3-(1-methylethyl)-; 3-isopropyl-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione; 1-Hydroxy-3-(propan-2-yl)-6,7,8,8a-tetrahydropyrrolo[1,2-a]pyrazin-4(3H)-one; NCGC00381364-01!3-propan-2-yl-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione
|
|
CAS | 5654-87-5 | |
PubChem CID | 98951 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 196.25 | ALogp: | 0.8 |
HBD: | 1 | HBA: | 2 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 49.4 | Aromatic Rings: | 2 |
Heavy Atoms: | 14 | QED Weighted: | 0.665 |
Caco-2 Permeability: | -4.638 | MDCK Permeability: | 0.00000872 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.03 |
Human Intestinal Absorption (HIA): | 0.008 | 20% Bioavailability (F20%): | 0.004 |
30% Bioavailability (F30%): | 0.021 |
Blood-Brain-Barrier Penetration (BBB): | 0.948 | Plasma Protein Binding (PPB): | 28.74% |
Volume Distribution (VD): | 0.772 | Fu: | 69.96% |
CYP1A2-inhibitor: | 0.016 | CYP1A2-substrate: | 0.121 |
CYP2C19-inhibitor: | 0.043 | CYP2C19-substrate: | 0.753 |
CYP2C9-inhibitor: | 0.022 | CYP2C9-substrate: | 0.48 |
CYP2D6-inhibitor: | 0.012 | CYP2D6-substrate: | 0.208 |
CYP3A4-inhibitor: | 0.026 | CYP3A4-substrate: | 0.312 |
Clearance (CL): | 6.438 | Half-life (T1/2): | 0.764 |
hERG Blockers: | 0.006 | Human Hepatotoxicity (H-HT): | 0.687 |
Drug-inuced Liver Injury (DILI): | 0.257 | AMES Toxicity: | 0.015 |
Rat Oral Acute Toxicity: | 0.286 | Maximum Recommended Daily Dose: | 0.037 |
Skin Sensitization: | 0.082 | Carcinogencity: | 0.028 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.021 |
Respiratory Toxicity: | 0.046 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005207 | 1.000 | D02IIW | 0.233 | ||||
ENC005973 | 1.000 | D0Q5NX | 0.230 | ||||
ENC005409 | 1.000 | D0I0EG | 0.230 | ||||
ENC004972 | 0.756 | D0S8LV | 0.220 | ||||
ENC005974 | 0.681 | D0R2KF | 0.219 | ||||
ENC005708 | 0.681 | D04CSZ | 0.218 | ||||
ENC001907 | 0.681 | D05QIM | 0.217 | ||||
ENC002258 | 0.651 | D0E1XL | 0.207 | ||||
ENC004743 | 0.651 | D0N4EC | 0.204 | ||||
ENC000991 | 0.468 | D0P7VJ | 0.203 |